Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you expect biotech companies and those involved in genome research to thrive over time as our aging population's medical needs grow, the PowerShares Dynamic Biotech & Genome ETF
ETFs often sport lower expense ratios than their mutual fund cousins. The biotech and genome ETF's expense ratio -- its annual fee -- is 0.63%.
This ETF has performed reasonably, underperforming the S&P 500, on average, over the past three years, but beating it over the past five. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver. The fund is relatively small, too, so if you're thinking of buying, beware of occasionally large spreads between its bid and ask prices. Consider using a limit order if you want to buy in.
What's in it?
Many companies in this industry had strong performances over the past year. Amylin Pharmaceuticals
Other companies didn't do as well last year, but they could see their fortunes change in the coming years. Vertex Pharmaceuticals
Then there's Nektar Therapeutics
The big picture
Demand for new drugs and medical treatments isn't going away any time soon. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.
Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter here, holds no position in any company mentioned. Click here to see her holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.